Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study

Journal of Cystic Fibrosis

Volumn 6, Issue 5, 2007, Pages 320-326

  Durieu, Isabelle ^a   Vericel, Evelyne ^b   Guichardant, Daniel ^b   Roth, Hubert ^c   Steghens, Jean Paul ^d   Drai, Jocelyne ^e   Nove Josserand, Raphaele ^a   Fontaine, Eric ^c   Lagarde, Michel ^b   Bellon, Gabriel ^f  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ DE LYON   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f EA 3096   (France)

Author keywords

Cystic fibrosis; Intravenous fish oil treatment; n 3 fatty acids; Oxidative stress; Platelet

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; FISH OIL; GLUTATHIONE; LIPID EMULSION; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OMEGAVENOUS; PANCREAS ENZYME; RETINOL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BRONCHITIS; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG SAFETY; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; HUMAN; LIPID PEROXIDATION; LUNG DISEASE; OBSERVATIONAL STUDY; OPEN STUDY; OXIDATIVE STRESS; PANCREAS INSUFFICIENCY; SCHOOL CHILD; THROMBOCYTE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; GLUTATHIONE PEROXIDASE; HUMANS; INJECTIONS, INTRAVENOUS; OXIDATION-REDUCTION; PILOT PROJECTS;

EID: 34548235901     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.12.005     Document Type: Article

References (32)

1. Strandvik B., Gronowitz E., Enlund F., Martisson T., and Wahlström J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 139 (2001) 650-655
2. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 350 (2004) 560-569
3. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., and Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/-mice. PNAS 96 (1999) 13995-14000
4. Bhura Bandali F., Suh M., Man S.F.P., and Clandinin M.T. The DF508 mutation in the Cystic Fibrosis Transmembrane Conductance Regulator alters control of essential fatty acid utilization in epithelial cells. J Nutr 130 (2000) 2870-2875
5. Strandvik B., Brönnegerd M., Gilljam H., and Carlstedt-Duke J. Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis. Scand J Gastroenterol 23S (1988) 1-4
6. Craig-Schmidt M.C., Faircloth S.A., Teer P.A., Weete J.D., and Wu C.Y. The essential fatty acid deficient chicken as a model for cystic fibrosis. Am J Clin Nutr 6 (1986) 1268-1275
7. Wood L., Fitzgerald A.D., Gibson P.G., Cooper D.M., and Garg M.L. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis. Am J Clin Nutr 75 (2002) 668-675
8. Paredji P., Kharitonov S.A., and Barnes P.J. Analysis of expired air for oxidation products. Am J Respir Crit Care Med 166 (2002) S31-S37
9. Henderson W.R., Astley S.J., McCready M.M., Kushmerick P., Casey S., Becker J.W., et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 124 (1994) 400-408
10. Katz D.P., Manner T., Furst P., and Askanazi J. The use of an intravenous fish-oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 12 (1996) 334-339
11. DeVisia B., Raia V., Spano C., Pavlidis C., Coruzzo A., and Alessio M. Effect of an 8-month treatment with ω-3 fatty acids in patients with cystic fibrosis. J Parenter Enter Nutr 27 (2003) 52-57
12. Kurlandsky L.E., Benning M.R., and Phyllis M.W. The absorption and effect of dietary supplementation with ω-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 18 (1984) 211-217
13. Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 25 (2006) 418-427
14. GISSI-Prevenzione investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
15. Palozza P., Sgarlata E., Luberto C., Piccioni E., Anti M., Marra G., et al. N-3 fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation. Am J Clin Nutr 64 (1996) 297-304
16. Vericel E., Polette A., Bacot S., Calzada C., and Lagarde M. Pro-and antioxidant activities of docosahexaenoic acid on human blood platelets. J Thromb Haemost 1 (2003) 566-572
17. Lagarde M., Bryon P.A., Guichardant M., and Dechavanne M. A simple and efficient method for platelet isolation from their plasma. Thromb Res 17 (1980) 581-588
18. Bowyer D.E., Leat W.N., Howard A.N., and Geshon G.A. The determination of the fatty acid composition of serum lipids separated by thin layer chromatography and comparison with column chromatography. Biochim Biophys Acta 70 (1963) 423-431
19. Paglia D.E., and Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70 (1967) 158-169
20. Chaudière J., and Gérard D. Dosage de l'activité glutathion peroxidase. In: Douste-Blazy L., and Mendy F. (Eds). In Biologie des Lipides chez l'Homme (1988), Editions Médicales Internationales, Paris 275-279
21. Roveri A., Maiorino M., and Ursini F. Enzymatic and immunological measurements of soluble and membrane-bound phospholipid-hydroperoxide glutathione peroxidase. Methods Enzymol 233 (1994) 202-212
22. Lagrange-Puget M., Durieu I., Ecochard R., Abbas-Chorfa F., Drai J., Steghens J.P., et al. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. Pediatr Pulmonol 38 (2004) 43-49
23. Steghens J.P., Van Kappel A.L., Riboli E., and Collombel C. Simultaneous measurement of seven carotenoids, retinol and alpha-tocopherol in serum by high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 694 (1997) 71-81
24. Steghens J.P., Van Kappel A.L., Denis I., and Collombel C. Diaminonaphtalene, a new highly specific reagent for HPLC-UV measurement of total and free malondialdehyde in human plasma or serum. Free Radic Biol Med 31 (2001) 242-249
25. Arab K., and Steghens J.P. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 325 (2004) 158-163
26. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 300 (1999) 58-62
27. Steghens J.P., Flourie F., Arab K., and Collombel C. Fast liquid chromatography-mass spectrometry glutathione measurement in whole blood: micromolar GSSG is a sample preparation artifact. J Chromatogr B Analyt Technol Biomed Life Sci 798 (2003) 343-349
28. Guichardant M., Chantegrel B., Deshayes C., Doutheau A., Moliere P., and Lagarde M. Specific markers of lipid peroxidation issued from n-3 and n-6 fatty acids. Biochem Soc Trans (2004) 139-140
29. Wu G., Fang Y.Z., Yang S., Lupton J.R., and Turner N.D. Glutathione metabolism and its implications for health. J Nutr 134 (2004) 489-492
30. Lemaitre D., Vericel E., Polette A., and Lagarde M. Effects of fatty acids on human platelet glutathione peroxidase: possible role of oxidative stress. Biochem Pharmacol 53 (1997) 479-486
31. Allard J.P., Kurian RAghdass E., Mugli R., and Royall D. Lipid peroxidation during fatty acid and vitamin E supplementation in humans. Lipids 32 (1997) 535-541
32. Strandvik B. Fatty acid metabolism in cystic fibrosis. N Engl J Med 350 (2004) 605-607